Table 4.

Frequency of CAEs in ponatinib-treated patients

New-onset CAE	Cumulative incidence, n (%) (n = 78)*	Ponatinib 45 mg/d, n (%)	Ponatinib 30 mg/d, n (%)	Ponatinib 15 mg/d, n (%)
Arrhythmia	7 (9.0)	1 (1.3)	3 (3.8)	3 (3.8)
Hypertension	6 (7.7)	3 (3.8)	2 (2.6)	1 (1.3)
Venous thrombosis	4 (5.1)	1 (1.3)	3 (3.8)	0 (0.0)
Heart failure	4 (5.1)	1 (1.3)	2 (2.6)	1 (1.3)
Myocardial infarction	3 (3.8)	0 (0.0)	1 (1.3)	2 (2.6)
Arterial thrombosis†	1 (1.3)	0 (0.0)	1 (1.3)	0 (0.0)
Peripheral arterial disease	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Cerebrovascular accident	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

^*Four patients had >1 CAE.

^†Other than myocardial infarction or cerebrovascular accident.